Juhienah Khalaf | Director of Chemistry
Inimmune Corporation

Juhienah Khalaf is a medicinal chemist specializing in the design, synthesis, and development of bioactive compounds, including small-molecule immunomodulatory and protease inhibitors. With a strong foundation in medicinal and organic chemistry, she has advanced research on therapeutic molecules targeting immune responses and infectious diseases.  Her work includes the creation of TLR4 and TLR8 agonists and antagonists as small-molecule drugs and immune-based therapeutics, contributing to the development of novel adjuvant systems and targeted therapies. These efforts aim to address critical challenges in disease treatment and expand the availability of innovative adjuvants.  Notably, Juhienah synthesized INI-2002, a TLR4 agonist that has become the lead component of Inimmune's Adjuvant Systems. This pioneering work is being presented at the World Vaccine Congress (WVC) in Amsterdam, highlighting the potential of INI-2002 to enhance vaccine efficacy through targeted delivery systems designed to modulate immune responses.  In a joint presentation, Inimmune and SPI will showcase a suite of innovative adjuvant systems — affordable, accessible, and widely available — that tackle the global adjuvant access gap.